ARWR - Arrowhead Pharmaceuticals

None

Market Cap

$8.6B

Cash Runway

—

Pipeline

5 Assets

Priority

High

Investment Thesis

Bull Case

TRiM platform enables delivery to lung, muscle, and adipose tissue — not just liver
Plozasiran (REDEMPLO) approved Nov 2025 - first RNAi therapeutic for APOC3 with 80% TG reduction
ARO-INHBE targets INHBE gene, a validated obesity pathway; Phase 1 data showed 6-9% weight loss
Zodasiran Phase 3 recruiting in HoFH with 65% LDL-C reduction
Amgen and Takeda partnerships validate platform and provide commercial infrastructure

Bear Case

Alnylam dominates RNAi space with established commercial infrastructure
ARO-INHBE obesity data still early; 6-9% may not be competitive with GLP-1s (15-25%)
Partner concentration - Amgen and Takeda control key assets
sHTG competition from Ionis olezarsen (Tryngolza)
Execution risk on extra-hepatic delivery claims

Pipeline

Asset	Target	Stage	Lead Indication	Next Catalyst
ARO-ALK7	ALK7	Phase 1	Obesity	Phase 1/2 initial data (2026-2027)
ARO-INHBE	INHBE	Phase 1	Obesity	Phase 1/2 dose-expansion data (2026)
Fazirsiran	AAT	Phase 3	Alpha-1 Antitrypsin Deficiency Liver Disease (AATD-LD)	SEQUOIA Phase 3 data (2028)
Plozasiran	APOC3	Approved	Familial Chylomicronemia Syndrome (FCS)	sHTG PDUFA decision (H1 2026)
Zodasiran	ANGPTL3	Phase 2	Homozygous Familial Hypercholesterolemia (HoFH)	Phase 3 HoFH data (2026-2027)

Partnerships

Amgen

Plozasiran, Zodasiran

$35M / $617M

Development/Commercial

Takeda

Fazirsiran

$300M / $1,040M

Development/Commercial

Johnson & Johnson (Janssen)

JNJ-3989, JNJ-75220795

$250M / $1,600M

Development/Commercial

Data sourced exclusively from public filings, corporate presentations, and published clinical data. For informational purposes only. Not investment advice. Satya Bio does not provide recommendations to buy or sell securities. Terms · Privacy